Cargando…

Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life

BACKGROUND: Treatment efficacy and costs of anti-VEGF drugs have not been studied in clinical routine. OBJECTIVE: To compare treatment costs and clinical outcomes of the medications when adjusting for patients’ characteristics and clinical status. DESIGN: Comparative study. SETTING: The largest publ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmid, Martin K., Reich, Oliver, Faes, Livia, Boehni, Sophie C., Bittner, Mario, Howell, Jeremy P., Thiel, Michael A., Signorell, Andri, Bachmann, Lucas M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524713/ https://www.ncbi.nlm.nih.gov/pubmed/26241852 http://dx.doi.org/10.1371/journal.pone.0135050

Ejemplares similares

Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context
por: Schmid, Martin K., et al.
Publicado: (2018)

Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland
por: Reich, Oliver, et al.
Publicado: (2017)

Anti-VEGF treatment patterns and associated health care costs in Switzerland: findings using real-world claims data
por: Reich, Oliver, et al.
Publicado: (2015)

Colour Doppler analysis of ophthalmic vessels in the diagnosis of carotic artery and retinal vein occlusion, diabetic retinopathy and glaucoma: systematic review of test accuracy studies
por: Bittner, Mario, et al.
Publicado: (2016)

Comparison of Eylea® with Lucentis® as first-line therapy in patients with treatment-naïve neovascular age-related macular degeneration in real-life clinical practice: retrospective case-series analysis
por: Böhni, Sophie C., et al.
Publicado: (2015)

Real Life Multicenter Comparison of 24-Month Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-Aflibercept Switch
por: Kucukevcilioglu, Murat, et al.
Publicado: (2023)

Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
por: Jung, Byung Ju, et al.
Publicado: (2019)

Does Coordinated Postpartum Care Influence Costs?
por: Zemp, Elisabeth, et al.
Publicado: (2017)

Assessment of mouse VEGF neutralization by ranibizumab and aflibercept
por: Ichiyama, Yusuke, et al.
Publicado: (2022)

Health Care Utilisation and Transitions between Health Care Settings in the Last 6 Months of Life in Switzerland
por: Bähler, Caroline, et al.
Publicado: (2016)

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
por: Avery, Robert L., et al.
Publicado: (2017)

Place of death and health care utilization for people in the last 6 months of life in Switzerland: a retrospective analysis using administrative data
por: Reich, Oliver, et al.
Publicado: (2013)

Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Kiss, Szilárd, et al.
Publicado: (2020)

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
por: Demircan, Ali, et al.
Publicado: (2018)

Intensity of treatment in Swiss cancer patients at the end-of-life
por: Bähler, Caroline, et al.
Publicado: (2018)

Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
por: ROA Vandekerckhove, Kristof
Publicado: (2015)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015)

Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions
por: Giannos, Steven A., et al.
Publicado: (2018)

Ranibizumab non-response in pachychoroid neovasculopathy: Effects of switching to aflibercept
por: Schworm, Benedikt, et al.
Publicado: (2020)

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
por: Ohara, Hiromi, et al.
Publicado: (2023)

Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis
por: Hernandez, Luis, et al.
Publicado: (2018)

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis
por: Yu, Justin S, et al.
Publicado: (2021)

A Real-Life Study: Intravitreal Aflibercept, Ranibizumab and Dexamethasone for Macular Edema Secondary to Branch Retinal Vein Occlusion
por: Bayat, Alper Halil, et al.
Publicado: (2019)

Real-life outcomes of intravitreal ranibizumab, aflibercept, and dexamethasone implant administrations in patients with treatment-naïve diabetic macular edema
por: Korkmaz, Anil, et al.
Publicado: (2021)

Real-World Results of Aflibercept versus Ranibizumab for the Treatment of Exudative AMD Using a Fixed Regimen
por: Providência, Joana, et al.
Publicado: (2018)

Accuracy of a Self-monitoring Test for Identification and Monitoring of Age-related Macular Degeneration: A Diagnostic Case-control Study
por: Schmid, Martin K., et al.
Publicado: (2018)

How does hospitalization affect continuity of drug therapy: an exploratory study
por: Blozik, Eva, et al.
Publicado: (2016)

Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
por: Miura, Masahiro, et al.
Publicado: (2013)

Effects of a Single Intravitreal Injection of Aflibercept and Ranibizumab on Glomeruli of Monkeys
por: Tschulakow, Alexander, et al.
Publicado: (2014)

Aflibercept in refractory wet AMD treated with ranibizumab: Anatomical and visual outcome
por: Abou-Ltaif, Sleiman
Publicado: (2016)

Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells
por: Chae, Jae-Byoung, et al.
Publicado: (2018)

Acquired perforating collagenosis associated with ranibizumab injection and succesfully switched to aflibercept
por: Kanra, Ayse Yagmur, et al.
Publicado: (2018)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda, Sameh Mosaad, et al.
Publicado: (2017)

Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema
por: Shimizu, Norihiro, et al.
Publicado: (2017)

Assessment of Patient Pain Experience During Intravitreal Ranibizumab and Aflibercept Injection
por: Bilgin, Burak, et al.
Publicado: (2019)

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
por: Haensli, Christof, et al.
Publicado: (2021)

Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience
por: Kaya, Mahmut, et al.
Publicado: (2023)

Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema
por: Kourlaba, Georgia, et al.
Publicado: (2016)

Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study)
por: Gascon, Pierre, et al.
Publicado: (2021)

Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
por: Carrasco, Joao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rqf090v5kqiesponmgngmiflve